Federica Ruffini
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Pharmacological inhibition of PDGF-C/neuropilin-1 interaction: A novel strategy to reduce melanoma metastatic potential.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: February 24, 2024
Targeting of PDGF-C/NRP-1 autocrine loop as a new strategy for counteracting the invasiveness of melanoma resistant to braf inhibitors.
Journal: Pharmacological research
Published: August 19, 2022
Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Journal: Pharmacological research
Published: March 10, 2020
Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
Journal: Journal of cellular and molecular medicine
Published: September 02, 2019
Vascular endothelial growth factor receptor 1 in glioblastoma‑associated microglia/macrophages.
Journal: Oncology reports
Published: August 09, 2019
miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Journal: Journal of experimental & clinical cancer research : CR
Published: November 27, 2018
The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo.
Journal: The Journal of pharmacology and experimental therapeutics
Published: August 04, 2017
Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib.
Journal: Oncotarget
Published: August 03, 2017
The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.
Journal: Journal of experimental & clinical cancer research : CR
Published: July 10, 2017
Last Updated: 09/26/2026